Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 10, 2016, Pages

  Lunn, Michael P T ^a   Nobile Orazio, Eduardo ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN M ANTIBODY; MYELIN ASSOCIATED GLYCOPROTEIN ANTIBODY; PARAPROTEIN; PROTEIN ANTIBODY; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; MYELIN ASSOCIATED GLYCOPROTEIN;

ANTIBODY BLOOD LEVEL; DEMYELINATING NEUROPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; META ANALYSIS; PERIPHERAL NEUROPATHY; PLASMA EXCHANGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEROID THERAPY; SYSTEMATIC REVIEW; BLOOD; DEMYELINATING DISEASES; IMMUNOLOGY; PARAPROTEINEMIAS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROCEDURES;

DEMYELINATING DISEASES; HUMANS; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MYELIN-ASSOCIATED GLYCOPROTEIN; PARAPROTEINEMIAS; PARAPROTEINS; PERIPHERAL NERVOUS SYSTEM DISEASES; PLASMA EXCHANGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RITUXIMAB;

EID: 84990059472     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002827.pub4     Document Type: Review

References (103)

1. Comi G, Roveri L, Swan A, Willison H, Bojar M, Illa I, et al. Inflammatory Neuropathy Cause And Treatment (INCAT) Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. Journal of Neurology 2002;249(10):1370-7. [PUBMED: 12382151]
2. Dalakas MC, Quarles RH, Farrer RG, Dambrosia J, Soueidan S, Stein DP, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology 1996;40(5):792-5. [PUBMED: 8957021]
3. Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology 2009;65(3):286-93. [PUBMED: 19334068]
4. Léger JM, Viala K, Nicolas G, Créange A, Vallat JM, Pouget J, et al. Placebo controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 2013;80(24):2217-25. [PUBMED: 23667063]
5. Mariette X, Chastang C, Clavelou P, Louboutin J-P, Leger JM, Brouet JC. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry 1997;63(1):28-34. [PUBMED: 9221964]
6. Mariette X, Brouet JC, Chevret S, Leger JM, Clavelou P, Pouget J, et al. A randomized double blind trial versus placebo does not confirm the benefit of alpha-interferon in polyneuropathy associated with monoclonal IgM. Journal of Neurology, Neurosurgery and Psychiatry 2000;69(2):279-80. [PUBMED: 10960293]
7. Niermeijer JMF, Eurelings M, Van der Linden MW, Lokhorst HM, Franssen H, Fischer K, et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology 2007;69(1):50-9. [PUBMED: 17606880]
8. Oksenhendler E, Chevret S, Leger JM, Louboutin JP, Bussel A, Brouet JC. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. Journal of Neurology, Neurosurgery and Psychiatry 1995;59(3):243-7. [PUBMED: 7673949]
9. Barohn RJ, Rashid I, McVey AL, Herbelin L, Skikne B, Saperstein DS. Rituximab for the treatment of IgM associated polyneuropathies. Journal of the Peripheral Nervous System 2005;10 Suppl 1:4.
10. Benedetti L, Gobbi M, Ghiglione E, Vigo T, Carpo M, Cocito D, et al. Rituximab in anti-MAG polyneuropathy. Journal of the Peripheral Nervous System 2005;10(Suppl 1):5.
11. Benedetti B, Briani C, Grnadis M, Vigo T, Gobbi M, Ghiglione E, et al. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. Journal of the Peripheral Nervous System 2007;12(2):102-7.
12. Benedetti L, Briani C, Franciotta D, Carpo M, Padua L, Zara G, et al. Long-term effect of rituximab in anti-MAG polyneuropathy. Neurology 2008;71(21):1742-4.
13. Canavan JB, Moroney JT, Keogan MT, Hardiman O. Rituximab and IgM autoantibody-associated peripheral neuropathy: The Irish experience. Neurology 2002;Suppl 3:A233.
14. Dyck PJ, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. New England Journal of Medicine 1991;325(21):1482-6. [MEDLINE: 92049565]
15. Goldfarb AR, Weimer LH, Brannigan TH 3rd. Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy. Muscle & Nerve 2005;31(4):510-5.
16. Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004;63(4):715-7.
17. Gorson KC, Natarajan N, Ropper AH, Weinstein R Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle & Nerve 2007;35(1):66-9.
18. Hamidou MA, Belizna C, Wiertlewsky S, Audrain M, Biron C, Grolleau J, et al. Intravenous cyclophosphamide in refractory polyneuropathy associated with IgM monoclonal gammopathy: an uncontrolled open trial. American Journal of Medicine 2005;118(4):426-30.
19. Kilidireas C, Anagnostopoulos A, Karandreas N, Mouselimi L, Dimopoulos MA. Rituximab therapy in monoclonal IgM-related neuropathies. Leukemia & Lymphoma 2006;47(5):859-64.
20. Latov N, Sherman WH. Therapy of neuropathy associated with anti-MAG IgM monoclonal gammopathy with Rituxan (abstract). Neurology 1999;52 Suppl 2:A551.
21. Niermeijer JMF, Eurelings M, Lokhorst H, Franssen H, Fijnheer R, Wokke JHJ, et al. Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy. Neurology 2006;67(11):2076-9.
22. Niermeijer JM, Eurelings M, Lokhorst HL, Van der Pol WL, Franssen H, Wokke JH, et al. Rituximab for polyneuropathy with IgM monoclonal gammopathy. Journal of Neurology, Neurosurgery and Psychiatry 2009;80(9):1036-9.
23. Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. Journal of Neurology, Neurosurgery and Psychiatry 2003;74(4):485-9.
24. Renaud S, Gregor M, Fuhr P, Lorenz D, Deuschl G, Gratwohl A, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle & Nerve 2003;27(5):611-5.
25. Renaud S, Fuhr P, Gregor M, Schweikert K, Lorenz D, Daniels C, et al. High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology 2006;66(5):742-4.
26. Sghirlanzoni A, Solari A, Ciano C, Mariotti C, Fallica E, Pareyson D. Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients. Neurological Sciences 2000;21(1):31-7.
27. Smith BE, Suarez GA, Witzig TE, Stevens JC, Bosch EP, Ross MA, et al. A phase II trial of rituximab for peripheral neuropathy associated with monoclonal gammopathy of undetermined significance (MGUS). Journal of the Peripheral Nervous System 2011;16(Suppl s3):130.
28. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for the diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41(5):617-8.
29. Andres E, Vinzio S, Maloisel F, Carre S, Perrin AE, Goichot B, et al. Autoimmune peripheral neuropathies with anti-MAG antibodies and hematological disorders. Five cases [Neuropathies péripheriques auto-immunes a anticorps anti-MAG et hémopathies. À propos de 5 observations]. Annales de Médecine Interne 2001;152(3):147-51.
30. Bamford JM, Sandercock PA, Warlow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989;20(6):828.
31. Bland JH, Gennari FJ, Erschler WB, Latov N. IgMk monoclonal antibody directed against peripheral nerve myelin; clinical peripheral neuropathy and long-term rheumatic disease. Journal of Rheumatology 1985;12(6):1200.
32. Blume G, Pestronk A, Goodnough LT. Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology 1995;45(8):1577-80.
33. Broglio L, Lauria G. Worsening after rituximab treatment in anti-MAG neuropathy. Muscle & Nerve 2005;32(3):378-9.
34. Chassande B, Leger JM, Younes-Chennoufi AB, Bengoufa D, Maisonobe T, Bouche P, et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle & Nerve 1998;21(6):55-62.
35. Cook D, Dalakas MC, Galdi A, Biondi D, Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy [see comments]. Neurology 1990;40:212-4. [MEDLINE: 90137262]
36. Dalakas MC, Engel WK. Polyneuropathy with monoclonal gammopathy: studies of 11 patients. Annals of Neurology 1981;10(1):45-52. [MEDLINE: 81280471]
37. Delmont E, Jeandel PY, Hubert AM, Marcq L, Boucraut J, Desnuelle C. Successful treatment with rituximab of one patient with CANOMAD neuropathy. Journal of Neurology 2010;257(4):655-7.
38. Donofrio PD, Kelly JJ Jr. AAEE case report #17: Peripheral neuropathy in monoclonal gammopathy of undetermined significance. Muscle & Nerve 1989;12(1):1-8.
39. Dubas F, Pouplard-Barthelaix A, Delestre F, Emile J. Polyneuropathies with IgM monoclonal gammopathy. 12 cases. Revue Neurologique 1987;143(10):670-83.
40. Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O'Brien PC, Grina LA, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Annals of Neurology 1980;8(6):590-6.
41. Dyck PJ, Hughes RAC, O'Brien PC. Quantitating overall neuropathic symptoms, impairments and outcomes. In: Dyck PJ, Thomas PK editor(s). Peripheral Neuropathy. 4th Edition. Philadelphia: Elsevier Saunders, 2005:1031-53.
42. Ellie E, Vital A, Steck A, Boiron J-M, Vital C, Julien J. Neuropathy associated with 'benign' anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological and pathological findings and response to treatment in 33 cases. Journal of Neurology 1996;243(1):34-43.
43. Ernerudh J, Brodtkorb E, Olsson T, Vedeler CA, Nyland H, Berlin G. Peripheral neuropathy and monoclonal IgM with antibody activity against peripheral nerve myelin; effect of plasma exchange. Journal of Neuroimmunology 1986;11(3):171-8.
44. Ernerudh JH, Vrethem M, Andersen O, Lindberg C, Berlin G. Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy. Journal of Neurology, Neurosurgery and Psychiatry 1992;55(10):930-4.
45. Ferrari S, Morbin M, Nobile-Orazio E, Musso A, Tomelleri G, Bertolasi L, et al. Antisulfatide polyneuropathy: antibody-mediated complement attack on peripheral myelin. Acta Neuropathologica 1998;96(6):569-74.
46. Frayne D, Starke RJ. Peripheral neuropathy with gammopathy responding to plasmapheresis. Clinical and Experimental Neurology 1985;21:195-200.
47. Ghosh A, Littlewood T, Donaghy M. Cladribine in the treatment of IgM paraproteinaemic polyneuropathy. Neurology 2002;59(8):1290-1.
48. Gironi M, Saresella M, Ceresa L, Calvo M, Ferrante P, Merli F, et al. Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab. Haematologica 2006;91(6 Suppl):ECR 17.
49. Gono T, Matsuda M, Shimojima Y, Ishii W, Yamamoto K, Morita H, et al. Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody. Journal of Clinical Neuroscience 2006;13(6):683-7.
50. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48(2):321-8.
51. Gorson KC, Ropper AH, Weinberg DH, Weinstein R. Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle & Nerve 2001;24(6):778-86.
52. Gruson B, Ghomari K, Beaumont M, Garidi R, Just A, Merle P, et al. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. Journal of the Peripheral Nervous System 2011;16(3):180-5.
53. Haas DC, Tatum AH. Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin-associated glycoprotein paraproteinemia. Annals of Neurology 1988;23(4):394-6.
54. Hafler DA, Johnson D, Kelly JJ, Panitch R, Kyle R, Weiner HL. Monoclonal gammopathy and neuropathy; myelin associated glycoprotein reactivity and clinical characteristics. Neurology 1986;36(1):75-8.
55. Hays AP, Lee SS, Latov N. Immune reactive C3d on the surface of myelin sheaths in neuropathy. Journal of Neuroimmunology 1988;18(3):231-44.
56. Higgins JPT, Green S, editor(s) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
57. Hoang-Xuan K, Leger JM, Ben Younes-Chennoufi A, Saidi H, Bouche P, Baumann N, et al. Treatment of immune deficient neuropathies with intravenous polyvalent immunoglobulins. An open study of 16 cases. Revue Neurologique 1993;149(6-7):385-92.
58. Hodgkinson SJ, Pollard JD, McLeod JG. Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. Journal of Neurology, Neurosurgery and Psychiatry 1990;53(4):327-30.
59. Ilyas AA, Gu Y, Dalakas MC, Quarles RH, Bhatt S. Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. Journal of the Peripheral Nervous System 2008;193(1-2):87-93.
60. Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 1994;117(Pt 5):941-7.
61. Kelly JJ, Kyle RA, O'Brien PC, Dyck PJ. Prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981;31(11):1480-3.
62. Kelly JJ, Adelman LS, Berkman E, Bhan I. Polyneuropathies associated with IgM monoclonal gammopathies. Archives of Neurology 1988;45(12):1355-9.
63. Kelly JJ. Chronic peripheral neuropathy responsive to rituximab. Reviews in Neurological Diseases 2006;3(2):78-81.
64. Latov N, Sherman WH, Nemni R, Galassi G, Shyong JS, Penn AS, et al. Plasma cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral nerve myelin. New England Journal of Medicine 1980;303(11):618-21.
65. Latov N, Hays AP, Sherman WH. Peripheral neuropathy and anti-MAG antibodies. Critical Reviews in Neurobiology 1988;3(4):301-32.
66. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999;52(8):1701-4.
67. Léger JM, Younes-Chennoufi AB, Chassande B, Davila G, Bouche P, Baumann N, et al. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. Journal of Neurology, Neurosurgery and Psychiatry 1994;57(Suppl):46-9.
68. Meier C, Roberts K, Steck A, Hess C, Miloni E, Tschopp L. Polyneuropathy in Waldenstrom's macroglobulinaemia: reduction of endoneurial IgM-deposits after treatment with chlorambucil and plasmapheresis. Acta Neuropathologica 1984;64(4):297-307.
69. Melmed C, Frail D, Duncan I, Braun P, Danoff D, Finlayson M, et al. Peripheral neuropathy with IgM kappa monoclonal immunoglobulin directed against myelin-associated glycoprotein. Neurology 1983;33(11):1397-405. [MEDLINE: 84040255]
70. Merkies IS, Schmitz PI, Samijn JP, Van der Meche FG, Van Doorn PA. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 1999;53(8):1648-54.
71. Merkies IS, Schmitz PI, Van der Meche FG, Van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 2000;54(4):943-9.
72. Monaco S, Bonetti B, Ferrari S, Moretto G, Nardelli E, Tedesco F, et al. Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. New England Journal of Medicine 1990;322(10):649-52. [MEDLINE: 90158704]
73. Nicolas G, Maisonobe T, Le Forestier N, Léger JM, Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle & Nerve 2002;25(1):26-30.
74. Niemierko E, Weinstein R. Response of patients with IgM and IgA-associated peripheral polyneuropathies to "off-line" immunoadsorption treatment using the Prosorba Protein A column. Journal of Clinical Apheresis 1999;14(4):159-62.
75. Nobile-Orazio E, Baldini L, Barbieri S, Marmiroli P, Spagnol G, Francomano E, et al. Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Annals of Neurology 1988;24(1):93-7.
76. Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000;123(Pt 4):710-7.
77. Noronha V, Fynan TM, Duffy T. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia. Journal of Clinical Oncology 2006;24(1):e3.
78. Notermans NC, Lokhorst HM, Franssen H, Van der Graaf Y, Teunissen LL, Jennekens FG, et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology 1996;47(5):1227-33.
79. Notermans NC, Vermeulen M, Lokhorst HM, Van Doorn PA, Van den Berg LH, Teunissen LL, et al. Pulsed high-dose dexamethasone treatment of polyneuropathy associated with monoclonal gammopathy. Journal of Neurology 1997;244(7):462-3.
80. Pouget J, Azulay JPH, Mesure S, Attarian S. Improvement of sensory ataxia in anti-MAG antibody associated polyneuropathy with interferon alpha: A posturographic study. Neurology 2000;54 Suppl 3:A47.
81. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
82. Rojas-García R, Gallardo E, De Andrés I, De Luna N, Juarez C, Sánchez P, et al. Chronic neuropathy with IgM antiganglioside antibodies: lack of long term response to rituximab. Neurology 2003;61(12):1814-6.
83. Rudnicki SA, Harik SI, Dhodapkar M, Barlogie B, Eidelberg D. Nervous system dysfunction in Waldenstrom's macroglobulinemia: response to treatment. Neurology 1998;51(4):1210-3.
84. Senn SJ. Cross-over Trials in Clinical Research. Chichester: Wiley, 1993.
85. Sherman WH, Olarte MR, McKiernan G, Sweeney K, Latov N, Hays AP. Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasia. Journal of Neurology, Neurosurgery and Psychiatry 1984;47(8):813-9.
86. Sherman WH, Latov N, Lange DE, Hays RD, Younger DS. Fludarabine for IgM antibody-mediated neuropathies. Annals of Neurology 1994;36:326-7. [ISSN 0364-5134]
87. Siciliano G, Moriconi L, Gianni G, Richieri E, Vignocchi MG, Rossi B. Selective techniques of apheresis in polyneuropathy associated with monoclonal gammopathy of undetermined significance. Acta Neurologica Scandanavica 1994;89(2):117-22.
88. Smith IS, Kahn SN, Lacey BW, King RHM, Eames RA, Whybrew DJ, et al. Chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. Brain 1983;106(Pt 1):169-95.
89. Smith T, Sherman W, Olarte MR, Lovelace RE. Peripheral neuropathy associated with plasma cell dyscrasia: a clinical and electrophysiological follow-up study. Acta Neurologica Scandanavica 1987;75(4):244-8.
90. Steck AJ, Kuntzer T. Anti-glycoconjugate antibodies and dysglobulinemic or dysimmune peripheral neuropathies. Revue Neurologique 1996;152:400-4.
91. Stefansson K, Marton L, Antel JP, Wollmann RL, Roos RP, Chejfec G, et al. Neuropathy accompanying IgM lambda monoclonal gammopathy. Acta Neuropathologica 1983;59(4):255-61.
92. Tagawa Y, Yuki N, Ohnishi A, Hirata K, Hosokawa S. Parameters for monitoring treatment effects in CIDP with anti-MAG/SGPG IgM antibody. Muscle & Nerve 2001;24(5):701-4.
93. Takatsu M, Hays AP, Latov N, Abrams GM, Nemni R, Sherman WH, et al. Immunofluorescence study of patients with neuropathy and IgM M proteins. Annals of Neurology 1985;18(2):173-81.
94. Tatum AH. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Annals of Neurology 1993;33(5):502-6.
95. Weide R, Heymanns J, Koppler H. The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab. British Journal of Haematology 2000;109(4):838-41.
96. Willison HJ, Trapp BD, Bacher JD, Dalakas MC, Griffin JW, Quarles RH. Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies. Muscle & Nerve 1988;11(11):1169-76.
97. Willison HJ, O'Leary CP, Veitch J, Blumhardt LD, Busby M, Donaghy M, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001;124(10):1968-77.
98. Wilson HC, Lunn MPT, Schey S, Hughes RAC. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. Journal of Neurology, Neurosurgery and Psychiatry 1999;66(5):575-80.
99. Yeung KB, Thomas PK, King RH, Waddy H, Will RG, Hughes RAC, et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. Journal of Neurology 1991;238(7):383-91.
100. Lunn MPT, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD002827]
101. Lunn MPT, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD002827]
102. Lunn MPT, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD002827.pub2]
103. Lunn MPT, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD002827.pub3]